Reversible pegylated drugs
US-2016324975-A1 · Nov 10, 2016 · US
US10913713B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10913713-B2 |
| Application number | US-201916679593-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 11, 2019 |
| Priority date | Nov 12, 2018 |
| Publication date | Feb 9, 2021 |
| Grant date | Feb 9, 2021 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The invention provides novel methods for preparing indolinobenzodiazepine dimer compounds and their synthetic precursors.
Opening claim text (preview).
The invention claimed is: 1. A method of preparing a compound of formula (IIIa): or a salt thereof, comprising the steps: (a) reacting a compound of formula (Ia): or a salt thereof, with a compound of formula (a): or a salt thereof, to form a compound of formula (IIa): (b) reacting the compound of formula (IIa) with a carboxylic acid deprotecting agent to form the compound of formula (IIIa), wherein E is —OH, halide or —C(═O)E is an activated ester; and P 1 is a carboxylic acid protecting group. 2. The method of claim 1 , wherein the method further comprises reacting the compound of formula (IIIa) with a compound of formula (IV): to form a compound of formula (Va): 3. The method of claim 1 , wherein P 1 is —O t Bu, —OMe, —OBn, or —O-silyl. 4. The method of claim 3 , wherein P 1 is —O t Bu. 5. The method of claim 1 , wherein E is —OH and the reaction between the compound of formula (Ia) and the compound of formula (a) is carried out in the presence of an activating agent. 6. The method of claim 5 , wherein the activating agent is a 2,4,6-trialkyl-1,3,5,2,4,6-trioxatriphosphorinane 2,4,6-trioxide, carbodiimide, a uronium, an activated ester, a phosphonium, 2-alkyl-1-alkylcarbonyl-1,2-dihydroquinoline, 2-alkoxy-1-alkoxycarbonyl-1,2-dihydroquinoline, or alkylchloroformate. 7. The method of claim 6 , wherein the activating agent is 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphorinane-2,4,6-trioxide. 8. The method of claim 1 , wherein the carboxylic acid deprotecting agent in step (b) is an acid. 9. The method of claim 8 , wherein the acid is trifluoroacetic acid (TFA). 10. The method of claim 1 , wherein the method comprises the steps of: (a) reacting a compound of formula (Ia1): or a salt thereof, with a compound of formula (a): or a salt thereof, in the presence of an activating agent to form a compound of formula (IIa1): (b) reacting the compound of formula (IIa1) with a carboxylic acid deprotecting agent to form the compound of formula (IIIa). 11. A method of preparing a compound of formula (Va): comprising the steps of: (a) reacting a compound of formula (Ia): or a salt thereof, with a compound of formula (a): or a salt thereof, to form a compound of formula (IIa): (b) reacting the compound of formula (IIa) with a carboxylic acid deprotecting agent to form the compound of formula (IIIa): or a salt thereof; and (c) reacting the compound of formula (IIIa) with a compound of formula (IV): to form the compound of formula (Va), wherein E is —OH, halide or —C(═O)E is an activated ester; and P 1 is a carboxylic acid protecting group. 12. The method of claim 11 , wherein P 1 is —O t Bu, —OMe, —OBn, or —O-silyl. 13. The method of claim 12 , wherein P 1 is —O t Bu. 14. The method of claim 11 , wherein E is —OH and the reaction between the compound of formula (Ia) and the compound of formula (a) is carried out in the presence of an activating agent. 15. The method of claim 14 , wherein the activating agent is a 2,4,6-trialkyl-1,3,5,2,4,6-trioxatriphosphorinane 2,4,6-trioxide, carbodiimide, a uronium, an activated ester, a phosphonium, 2-alkyl-1-alkylcarbonyl-1,2-dihydroquinoline, 2-alkoxy-1-alkoxycarbonyl-1,2-dihydroquinoline, or alkylchloroformate. 16. The method of claim 15 , wherein the activating agent is 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphorinane-2,4,6-trioxide. 17. The method of claim 11 , wherein the carboxylic acid deprotecting agent in step (b) is an acid. 18. The method of claim 17 , wherein the acid is trifluoroacetic acid (TFA). 19. The method of claim 11 , wherein the method comprises the steps of: (a) reacting a compound of formula (Ia1): or a salt thereof, with a compound of formula (a): or a salt thereof, in the presence of an activating agent to form a compound of formula (IIa1): (b) reacting the compound of formula (IIa1) with a carboxylic acid deprotecting agent to form a compound of formula (IIIa): or a salt thereof; and (c) reacting the compound of formula (IIIa) with a compound of formula (IV): to form the compound of formula (Va). 20. The method of claim 1 , wherein E, when present, is —OH and the reaction in step (a) is carried out in the presence of an activating agent that is HATU and HOAt.
Ortho-condensed systems · CPC title
with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom · CPC title
having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide · CPC title
with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide · CPC title
Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00 · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.